Patents Assigned to and Human
  • Mammary transforming protein
    Patent number: 6057434
    Abstract: A human mammary transforming protein and DNA (RNA) encoding such polypeptide and a procedure for producing such polypeptide by recombinant techniques is disclosed. Also disclosed are methods for inhibiting such polypeptide for preventing and/or treating neoplasia. Diagnostic assays for identifying mutations in nucleic acid sequence encoding a polypeptide of the present invention and for detecting altered levels of the polypeptide of the present invention for detecting diseases, for example, cancer, are also disclosed.
    Type: Grant
    Filed: November 1, 1996
    Date of Patent: May 2, 2000
    Assignee: Human Genome Sciences, Inc.
    Inventors: Jian Ni, Guo-Liang Yu, Reiner L. Gentz
  • Keratin K1 expression vectors and methods of use
    Patent number: 6057298
    Abstract: A keratin K1 vector for expression of a nucleic acid sequence in an epidermal cell. The vector includes a 5' flanking region which includes necessary sequences for expression of a nucleic acid cassette, a keratin K1 3' flanking region which regulates expression of a nucleic acid sequence, predominantly in the epidermis, and a linker which connects the 5' flanking region to a nucleic acid. The linker has a position for inserting a nucleic acid cassette. The linker does not contain the coding sequence of a gene that the linker is naturally associated with. That is, the linker is not the normal gene associated with the 5' and 3' regions.
    Type: Grant
    Filed: May 30, 1995
    Date of Patent: May 2, 2000
    Assignees: Baylor College of Medicine, The United States of America as represented by the Department of Health and Human Services
    Inventors: Dennis R. Roop, Joseph A. Rothnagel, David A. Greenhalgh, Stuart H. Yuspa
  • Selective elimination of T cells that recognize specific preselected targets
    Patent number: 6056952
    Abstract: This invention provides compositions and methods for the elimination of T cells that recognize specific preselected targets. The methods involve providing killer cells (e.g. natural killer cells or cytotoxic T lymphocytes) having a T cell receptor in which the zeta chain is joined to the antigen target of the T cell population it is desired to eliminate. Recognition of the antigen target activates the killer cell thereby inhibiting or destroying the T cell. Where the antigen target is the extracellular domain of a major histocompatibility complex, the method provides a means of mitigating graft rejection or an autoimmune response.
    Type: Grant
    Filed: June 2, 1998
    Date of Patent: May 2, 2000
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventor: Amy Sonya Rosenberg
  • Antibodies against human herpesvirus-6(HHV-6) and method of use
    Patent number: 6054283
    Abstract: A new human B lymphotropic virus, also designated human herpesvirus-6, has been isolated. DNA, molecular clones, antigenic viral proteins and antibodies having specificity to the new virus have been prepared. Various utilities of the new virus and products derived therefrom have been described.
    Type: Grant
    Filed: December 23, 1996
    Date of Patent: April 25, 2000
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Syed Zaki Salahuddin, Dharam V. Ablashi, Steven F. Josephs, Carl W. Saxinger, Flossie Wong-Staal, Robert C. Gallo
  • Polynucleotides encoding human ADA2
    Patent number: 6054289
    Abstract: Human polypeptides and DNA (RNA) encoding such polypeptides and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptide for therapeutic purposes. Antagonist against such polypeptides and their use as a therapeutic are also disclosed. Also disclosed are diagnostic methods for detecting disease which utilize the sequences and polypeptides.
    Type: Grant
    Filed: August 30, 1996
    Date of Patent: April 25, 2000
    Assignee: Human Genome Sciences, Inc.
    Inventor: Paul A. Moore
  • Recombinant proteins of a pakistani strain of hepatitis E and their use in diagnostic methods and vaccines
    Patent number: 6054567
    Abstract: The invention relates to the expression of open reading frame 2 (ORF-2) proteins of a strain of hepatitis E virus from Pakistan (SAR-55) in a eukaryotic expression system. The expressed proteins can serve as an antigen in diagnostic immunoassays and/or as an immunogen or vaccine to protect against infection by hepatitis E.
    Type: Grant
    Filed: April 11, 1997
    Date of Patent: April 25, 2000
    Assignees: The United States of America as represented by the Department of Health and Human Services, Novavax, Inc.
    Inventors: Suzanne U. Emerson, Robert H. Purcell, Sergei A. Tsarev, Robin A. Robinson
  • Arginase II
    Patent number: 6054308
    Abstract: The invention relates to Arginase II polypeptides, polynucleotides encoding the polypeptides, methods for producing the polypeptides, in particular by expressing the polynucleotides, and agonists and antagonists of the polypeptides. The invention further relates to methods for utilizing such polynucleotides, polypeptides, agonists and antagonists for applications, which relate, in part, to research, diagnostic and clinical arts.
    Type: Grant
    Filed: July 15, 1998
    Date of Patent: April 25, 2000
    Assignees: SmithKline Beecham Corporation, Human Genome Sciences, Inc.
    Inventors: Joseph G Vockley, Patrick J Dillon
  • Human MutY
    Patent number: 6051222
    Abstract: A human mutY polypeptide and DNA (RNA) encoding such polypeptide and a procedure for producing such polypeptide by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptide for preventing and/or treating diseases associated with a mutation in this gene. Diagnostic assays for identifying mutation in nucleic acid sequence encoding a polypeptide of the present invention and for detecting altered levels of the polypeptide of the present invention for detecting diseases, for example, cancer, are also disclosed.
    Type: Grant
    Filed: March 29, 1999
    Date of Patent: April 18, 2000
    Assignee: Human Genome Sciences, Inc.
    Inventor: Ying-Fei Wei
  • Heparin and sulfatide binding peptides from the type-I repeats of human thrombospondin and conjugates thereof
    Patent number: 6051549
    Abstract: This invention identifies a biologically active group of peptide sequences from Type I repeat units of the extracellular matrix protein, human thrombospondin-1, identical or homologous to the sequence, KRFKQDGGWSHWSPWSSC (SEQ ID NO.30). The biological activities residing with the full sequences, portions thereof, and variants of the full or partial sequences are disclosed. The invention describes how biological activity may be enhanced by covalently linking these peptides to suitable carriers, preferably a branched, water-soluble polymer of low (or absent) toxicity and immunogenicity, such as polysucrose (Ficoll.TM.). The invention describes (1) a method for preparing such conjugates, (2) the use of the defined peptides or their conjugates in blocking or modifying the action on cellular processes of heparin (e.g.
    Type: Grant
    Filed: March 11, 1998
    Date of Patent: April 18, 2000
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: David D. Roberts, Henry C. Krutzsch, Nenghua Guo
  • Constructs encoding recombinant antibody-toxin fusion proteins
    Patent number: 6051405
    Abstract: The present invention describes constructs encoding recombinant scFv-toxin fusion proteins which selectively kill cells bearing appropriate antigens or receptors.
    Type: Grant
    Filed: April 8, 1992
    Date of Patent: April 18, 2000
    Assignees: The United States of America as represented by the Secretary of the Department of Health and Human Services, Protein Design Labs, Inc.
    Inventors: David FitzGerald, Vijay Kumar Chaudhary, Ira Harry Pastan, Thomas Alexander Waldmann, Cary L Queen
  • Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule
    Patent number: 6045802
    Abstract: The present invention is a composition of recombinant virus which has incorporated into its genome or portion thereof a gene encoding an antigen to a disease causing agent and a recombinant virus which has incorporated into its genome or portion thereof a gene encoding an immunostimulatory molecule(s) for the purpose of stimulating an immune response against the disease causing agent. Methods of treatment of diseases such as cancer and diseases caused by pathogenic microorganisms is provide using the composition.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: April 4, 2000
    Assignee: The United States of America as represented by the Secretary of the Department Of Health and Human Services
    Inventors: Jeffrey Schlom, Judith Kantor, James W. Hodge
  • Procedure to block the replication of reverse transcriptase dependent viruses by the use of inhibitors of deoxynucleotides synthesis
    Patent number: 6046175
    Abstract: A method for inhibiting replication of reverse transcriptase dependent virus in plant or animal cells, comprising the step of administering to said cells a compound that depletes the intracellular pool of deoxyribonucleoside phosphate in an amount effective to inhibit replication of said virus. Hydroxyurea is one such suitable compound. Also disclosed is a method for producing incomplete reverse-transcriptase dependent viral DNA, by administering a deoxyribonucleoside phosphate-depleting drug to cells infected with such a virus.
    Type: Grant
    Filed: May 17, 1994
    Date of Patent: April 4, 2000
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Franco Lori, Andrea Cara, Wen-Yi Gao, Robert C. Gallo
  • Metalloproteinases
    Patent number: 6046031
    Abstract: The present invention relates to novel metalloproteinase-like proteins. In particular, isolated nucleic acid molecules are provided encoding the human TACE-like and matrilysin-like proteins. TACE-like and matrilysin-like polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TACE-like and matrilysin-like activity. Also provided are diagnostic methods for detecting cancer and therapeutic methods for cancer and other disorders characterized by an over or under production of these metalloproteinases.
    Type: Grant
    Filed: January 20, 1998
    Date of Patent: April 4, 2000
    Assignee: Human Genome Sciences, Inc.
    Inventors: Jian Ni, Steve Ruben, Laurie Brewer, Reiner Gentz, Craig Rosen
  • Anti-viral pharmaceutical compositions containing saturated 1,2-dithiaheterocyclic compounds and uses thereof
    Patent number: 6046228
    Abstract: The present invention is directed to pharmaceutical compositions including a saturated 1,2-dithiaheterocyclic compound having antiviral activity. The present invention also provides a kit containing the pharmaceutical composition and methods of treating or preventing viral disease using the composition, as well as methods for inactivating retrovirus in a body fluid.
    Type: Grant
    Filed: January 4, 1999
    Date of Patent: April 4, 2000
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: William G. Rice, Robert R. Schultz, David C. Baker, Louis E. Henderson
  • Compositions having neuroprotective and analgesic activity
    Patent number: 6046200
    Abstract: Compounds of the formula: ##STR1## wherein R.sup.1 and R.sup.2 are alkyl of 1-8 carbons have been shown to have both neuroprotective and analgesic activities. The compounds of the invention may be used in treatment of conditions that would normally result in neuronal damage, including those arising on account of cerebral ischemia/hypoxia or increase in intracranial pressure such as neoplasms, stroke, meningitis or trauma. Compositions of the invention can also be useful for treatment of toxin-related damage such as drug over-dose or exposure to toxins in the environment.
    Type: Grant
    Filed: January 20, 1998
    Date of Patent: April 4, 2000
    Assignees: The United States of America as represented by the Secretary of the Army, The United States of America as represented by the Department of Health and Human Services
    Inventors: Frank C. Tortella, Mark A. DeCoster, Kenner C. Rice, Sylvia N. Calderon
  • Polynucleotides encoding a cardiotrophin-like cytokine
    Patent number: 6046035
    Abstract: The present invention relates to a novel CLC protein which is a member of the IL-6 cytokine family. In particular, isolated nucleic acid molecules are provided encoding the human CLC protein. CLC polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of CLC activity. Also provided are diagnostic methods for detecting cardiac and immune system-related disorders and therapeutic methods for treating cardiac and immune system-related disorders.
    Type: Grant
    Filed: June 29, 1998
    Date of Patent: April 4, 2000
    Assignee: Human Genome Sciences, Inc.
    Inventors: Yanggu Shi, Steven M. Ruben
  • Bystander effect tumoricidal therapy by expressing an HSV-tk gene
    Patent number: 6045789
    Abstract: A method for treating an tumor involves the initial identification of the tumor as one displaying a "bystander effect," whereby in vivo transfer of a gene conferring sensitivity to chemotherapeutic agent affects both transformed and non-transformed tumor cells. Into a tumor thus characterized is introduced in situ a retroviral vector containing the sensitizing gene. The retroviral vector, which may replication-defective or replication-competent, can be introduced directly (if it is replication-competent) or can be provided by means of a packaging cell line. Treatment of the patient with the chemotherapeutic agent thereafter effects tumor regression when as few as 10% of tumor cells are transformed, while normal tissue is not damaged. The anti-tumor impact of the treatment can be increased when the transducing vector also encodes an immune response-enhance substance such as IL-2 or another cytokine.
    Type: Grant
    Filed: July 13, 1994
    Date of Patent: April 4, 2000
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Kenneth W. Culver, R. Michael Blaese
  • Oligomeric HIV-1 envelope glycoproteins
    Patent number: 6039957
    Abstract: The present invention relates to methods for producing recombinant HIV-1 envelope (env) oligomers for use as immunogens. When gp140 oligomeric glycoproteins were purified by sucrose velocity gradient sedimentation, and then used to immunize mice, the resulting humoral immune response was skewed toward the production of antibodies that recognize conformation-dependent epitopes on the HIV-1 env protein. Assays for HIV-1 infections are described, as well as immonogens for vaccinating against HIV-1 infection.
    Type: Grant
    Filed: March 3, 1997
    Date of Patent: March 21, 2000
    Assignee: United States of America, as represented by the Department of Health and Human Services
    Inventors: Patricia L. Earl, Christopher C. Broder, Robert W. Doms, Bernard Moss
  • Vascular endothelial growth factor 2
    Patent number: 6040157
    Abstract: Disclosed are human VEGF2 polypeptides, biologically active, diagnostically or therapeuticall sefl fragments, analogs, or derivatives thereof, and DNA (RNA) enco such VEGF2 polypeptides. Also provided are procedures for producing such polypeptides by recombinant techniques and antibodies and antagonists against such polypeptides. Such polypeptides may be used therapeutically for stimulating wound healing and for vascular tissue repair. Also provided are methods of using the antibodies and antagonists to inhibit tumor angiogenesis and thus tumor growth, inflammation, diabetic retinopathy, rheumatoid arthritis, and psoriasis.
    Type: Grant
    Filed: March 13, 1998
    Date of Patent: March 21, 2000
    Assignee: Human Genome Sciences, Inc.
    Inventors: Jing-Shan Hu, Craig A. Rosen, Liang Cao
  • Use of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme a reductase as a modality in cancer therapy
    Patent number: 6040334
    Abstract: Methods of treating various cancers, such as prostatic adenocarcinoma, with inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG Co-A), such as lovastatin, are provided. Dosing ranges, schedules and toxicities are included.
    Type: Grant
    Filed: October 20, 1994
    Date of Patent: March 21, 2000
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Charles Myers, Jane Trepel, Won Ki Kang, Luke Whitesell, Len Neckers